NCT05728879View on ClinicalTrials.gov

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cutaneous T Cell Lymphoma
Interventions
COMBINATION_PRODUCT

APR-TD011 (RLF-TD011)

APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.

Trial Locations (1)

60611

Dermatology CTU, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER